Heterogeneity in adverse events related to atezolizumab-bevacizumab for hepatocellular carcinoma reported in real-world studies

Background & Aims: Safety data for patients with hepatocellular carcinoma (HCC) treated with atezolizumab-bevacizumab in the real-world setting remain uncertain. Thus, the aim of this study was to evaluate the incidence of adverse events (AEs) in patients with HCC treated with atezolizumab-bevac...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Claudia Campani, Dimitrios Pallas, Sabrina Sidali, Olga Giouleme, Lorraine Blaise, Véronique Grando, Gisele Nkontchou, Alix Demory, Pierre Nahon, Nathalie Ganne-Carrié, Jean-Charles Nault
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2024-11-01
Edice:	JHEP Reports
Témata:	liver cancer immunotherapy adverse effects
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2589555924001940
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!